bioAffinity Technologies to host veteran lung cancer webinar July 21, 2026

bioAffinity Technologies, Inc.

Webinar features Philips, 4DMedical, and NAVREF discussing lung health screening for veterans.
CyPath Lung test cited: 92% sensitivity, 87% specificity, 99% NPV in published trial.
Event is educational; no financial guidance or operational updates provided.
No changes to company outlook or product commercialization disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.